Insmed (INSM) Q2 2024 earnings summary

Executive summary

• Q2 2024 marked a pivotal quarter with total revenue of $90.3 million, up 17% year-over-year, driven by record ARIKAYCE sales growth in all regions and positive Phase 3 ASPEN data for brensocatib in bronchiectasis.

• Brensocatib launch preparation is a top priority, with NDA filing on track for Q4 2024 and anticipated U.S. launch mid-2025; commercial, medical, and payer engagement efforts are well underway.

• Strong cash position of $1.25 billion following a $713 million equity raise, supporting ongoing pipeline and launch activities.

• Net loss for Q2 2024 was $300.6 million ($1.94/share), compared to $244.8 million in Q2 2023.

• ENCORE trial enrollment target increased to 400, with top-line results expected Q1 2026 to support ARIKAYCE label expansion.

Financial highlights

• Q2 2024 global net revenues reached $90.3 million, up from $77.2 million in Q2 2023, with all-time high ARIKAYCE sales in the U.S. ($63.8M), Japan ($21.1M), and Europe/ROW ($5.4M).

• Gross-to-net in the U.S. was 15.4%; cost of product revenues was $21 million (23.2% of revenues); gross margin (excluding amortization) was 76.8%.

• R&D expenses were $146.7 million, down from $197 million year-over-year; SG&A expenses increased to $106.6 million, reflecting pipeline and launch investments.

• Operating loss for Q2 2024 was $288.9 million; net loss per share was $1.94.

• Non-cash charge of ~$104 million related to contingent consideration liabilities due to stock price changes.

Outlook and guidance

• Full-year 2024 global revenue guidance reiterated at $340–$360 million, representing 15% year-over-year growth at midpoint.

• Brensocatib NDA filing expected Q4 2024; U.S. launch targeted for mid-2025; launches in Europe and Japan expected in H1 2026.

• ENCORE trial top-line results expected Q1 2026; ARIKAYCE label expansion could drive product to $1B+ annual sales.

• Phase 2 readouts for brensocatib in CRS and TPIP in PAH expected in 2025; Phase 3 TPIP in PH-ILD to begin in 2025.

• Sufficient funds to meet financial needs for at least the next 12 months; may opportunistically raise additional capital.